

<https://doi.org/10.1038/s41531-024-00701-6>

Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson's disease

Check for updates

Anna Sauerbier^{1,2}✉, Johanna Herberg¹, Vasilija Stopic¹, Philipp A. Loehrer³, Keyoumars Ashkan⁴, Alexandra Rizos⁴, Stefanie T. Jost¹, Jan Niklas Petry-Schmelzer¹, Alexandra Gronostay¹, Christian Schneider¹, Veerle Visser-Vandewalle⁵, Julian Evans⁶, Christopher Nimsy⁷, Gereon R. Fink^{1,8}, Angelo Antonini⁹, Pablo Martinez-Martin¹⁰, Monty Silverdale⁶, Daniel Weintraub¹¹, Anette Schrag¹², K. Ray Chaudhuri^{2,4}, Lars Timmermann³, Haidar S. Dafsari¹✉ & EUOPAR, the German Parkinson Society Non-motor Symptoms Study Group, and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group*

The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson's disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of $\frac{1}{2}$ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged $63.1 \text{ years} \pm 8.3$ with $10.4 \text{ years} \pm 4.5$ PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.

Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL), and both motor and non-motor symptoms (NMS) in patients with Parkinson's disease (PD)^{1–3}. Present in 55.8% of patients with PD⁴, anxiety is one of the most prevalent NMS in PD. Literature shows that worse severity of anxiety is related to worse QoL and has an important impact on functioning in PD⁵. Unfortunately, anxiety is still underrecognised and

undertreated in PD patients in clinical practice⁶. Previous studies have shown that neurodegeneration of the striatum and dopaminergic and serotonergic pathways is linked to anxiety in PD⁷. However, the exact pathomechanisms of anxiety in PD are still not fully understood. Nevertheless, there is Class I evidence for beneficial effects of STN-DBS on anxiety⁸. A meta-analysis has showed that the effects of STN-DBS on anxiety are highly

A full list of affiliations appears at the end of the paper. *A list of authors and their affiliations appears at the end of the paper.

✉ e-mail: anna.sauerbier@uk-koeln.de; haidar.dafsari@uk-koeln.de



heterogeneous across study cohorts⁹. Differences in baseline characteristics of study cohorts may contribute to the heterogeneity of results, and it is not clear if patient demographic and preoperative clinical parameters are predictors of postoperative anxiety outcomes.

We tested the hypotheses (1) that patients with PD undergoing STN-DBS with preoperative anxiety experience an improvement of anxiety and (2) that preoperative clinical predictors of the postoperative changes of anxiety can be identified. Furthermore, we explored the relationship between the postoperative changes of anxiety and QoL.

Results

In total, 163 consecutive PD patients were screened and underwent a 6-month follow-up postoperatively between August 2015 and March 2020. Of these, 151 patients (92 male) with a mean age of $61.5 \text{ years} \pm 8.7$ and a mean disease duration of $10.4 \text{ years} \pm 4.7$ were included in the final analysis (see Fig. 1). The cut-off for a clinically relevant change in HADS-A was 1.8 points ($\frac{1}{2}$ SD of HADS-A_{baseline} in the overall cohort, see Supplementary Table 1). In the overall cohort, 33.1% (50/151) of patients (27 male) scored ≥ 8 on the HADS-A at baseline and were classified as anxiety cohort. Their mean age was $63.1 \text{ years} \pm 8.3$ and mean disease duration $10.4 \text{ years} \pm 4.5$. Fewer patients scored ≥ 8 on the HADS-D at baseline (21.2% of patients, 32/151). None of the patients of our overall cohort fulfilled diagnostic criteria of anxiety disorders according to DSM-V or ICD-10 criteria during the course of our study.

Clinical parameters at baseline and 6-month follow-up

Here we report the results of the anxiety cohort unless stated otherwise. HADS-A improved from baseline to follow-up (see Fig. 2). All other outcomes also improved at 6-month follow-up (see Table 1). The effect size was ‘large’ for HADS-A, HADS total, NMSS total, SCOPA-M motor complications, and LEDD total, ‘moderate’ for HADS-D, PDQ-8 SI, SCOPA-M ADL, and ‘small’ for LEDD-DA.

We observed a clinically relevant improvement in HADS-A in 80% of patients (40/50), a worsening of anxiety in 6% (3/50) and no clinically relevant anxiety change in 14% (7/50). Therefore, the $\text{NNT}_{\text{anxiety improvement}}$ was 1.25. The proportion of patients who reported HADS-A ≥ 8 at 6-month follow-up was 18.5% (relative risk reduction: 44.1%, absolute risk reduction: 14.6%, $\text{NNT}_{\text{anxiety remission}}$: 6.85).

Five patients were on a stable antidepressant medication regimen without changes of the drug or the dosage at baseline and 6-month follow-up. In three patients, an antidepressant medication was started between baseline and 6-month follow-up visits because of a depressive episode. None of the patients were treated with anxiolytic medication (e.g. benzodiazepines) between baseline and follow-up.

Correlation analyses

Explorative correlation analyses between HADS-A change scores and clinical characteristics at baseline are shown in Table 2. These correlations were ‘moderate’ for baseline SCOPA-ADL and ‘weak’ for baseline HADS total and HADS-A. In partial correlations, we found these relationships to remain significant after controlling for baseline HADS-D. These partial correlations were ‘small’ for baseline SCOPA-ADL ($r = .42$, $p = 0.003$) and HADS-A ($r = 0.30$, $p = 0.036$). No significant correlations were found between HADS-A change score and age, disease duration, baseline NMSS domains and levodopa equivalent daily dose.

Furthermore, we explored the relationship between HADS-A change score and change scores of other clinical parameters, which was ‘moderate’ for the PDQ-8 SI ($r = 0.47$, $p < 0.001$) and ‘negligible’ or ‘weak’ for other parameters.

Predictor analysis

Simple univariate linear regression analyses with HADS-A change score as the criterion variable were performed using candidate predictor variables




Fig. 1 | Flow chart of recruitment and data acquisition. DBS Deep Brain Stimulation, MMSE Mini Mental Status Examination, HADS Hospital Anxiety and Depression Scale.




Fig. 2 | Hospital Anxiety and Depression Scale-anxiety subscale outcomes.

Anxiety significantly improved at 6-month follow-up compared to baseline. The centre line illustrates median, the bounds of box represent the interquartile range (quartile 1 – quartile 3) and the whiskers extend to the furthest data point in each wing that is within 1.5 times the interquartile range. 6 MFU 6-month follow up, HADS-A Hospital Anxiety and Depression Scale-anxiety subscale, pts points.

identified in correlation analyses (relaxed threshold $p < 0.2$)^{10,11}. This additionally included the following variables at baseline: HADS-D ($r = 0.24$, $p = 0.101$), disease duration ($r = -0.19$, $p = 0.198$), UPDRS-motor examination ($r = 0.24$, $p = 0.105$), NMSS urinary domain ($r = 0.22$, $p = 0.117$), and LEDD ($r = -0.24$, $p = 0.093$).

Simple univariate regression analyses with HADS-A change score at 6-month follow-up as the criterion variable were significant for the following independent variables: HADS total score ($\beta = 0.36$, $p = 0.010$), HADS-A ($\beta = 0.40$, $p = 0.004$), SCOPA-ADL ($\beta = 0.46$, $p < 0.001$), and NMSS domain urinary ($\beta = 0.30$, $p = 0.033$).

For the regression analyses, we excluded the variable HADS total score at baseline due to high intercorrelation with HADS-A at baseline ($r = 0.70$, $p < 0.001$). In the stepwise multiple regression analysis, the variables SCOPA-ADL and NMSS urinary domain remained significant. The multivariate multiple regression model accounted for 26.0% of the variance ($R^2_{\text{corr}} = 0.260$) in HADS-A change score. In this model, SCOPA-ADL had the highest predictive value ($\beta = 0.42$, $p = 0.002$), followed by the NMSS urinary domain ($\beta = 0.29$, $p = 0.028$).

Overall cohort

In the overall cohort, we observed a clinically relevant improvement of anxiety in the majority of patients with 47.0% (71/151) of patients and a worsening of anxiety in 16.6% (25/151) of patients, whereas the remaining 36.4% (55/151) showed no clinically relevant change. Clinical characteristics of the overall cohort at baseline and 6-month follow-up are presented in Supplementary Table 2. At 6-month follow-

Table 1 | Clinical characteristics at baseline and 6 months follow-up

	Baseline			6-month follow-up			Relative change [%]	Effect size	p-value
	n	mean	SD	n	mean	SD			
HADS total	50	17.6	3.9	50	11.8	5.5	33.0	1.22	< 0.001
HADS-anxiety	50	10.3	1.7	50	6.1	3.0	40.8	1.72	< 0.001
HADS-depression	50	7.3	2.8	50	5.7	3.5	21.9	0.50	0.010
PDQ-8 SI	50	41.9	17.9	50	31.9	15.0	23.9	0.61	0.001
NMSS total	50	84.4	40.4	50	53.8	30.7	36.3	0.85	< 0.001
UPDRS-III	49	31.3	14.9	48	23.4	11.8	25.2	0.59	0.001
SCOPA-M ADL	49	8.4	3.1	50	6.4	3.6	23.8	0.60	0.001
SCOPA-M motor complications	49	6.1	2.7	49	3.6	2.4	41.0	0.98	< 0.001
LEDD total	50	1085.0	534.7	49	595.5	323.5	45.1	1.11	< 0.001
LEDD-DA	35	208.5	165.5	22	149.3	185.8	28.4	0.34	> 0.999

Wilcoxon signed rank or *t*-tests, when parametric test criteria were fulfilled, between baseline and 6-month follow-up to analyze within-group changes of clinical characteristics.
Bold font highlights significant results, *p* < 0.05.
All *p*-values are corrected for multiple comparisons using Bonferroni method.
We calculated relative change from baseline to follow-up [(mean Test_{baseline} – mean Test_{follow-up}) / mean Test_{baseline} x 100] and quantified effect size with Cohen's *d*.
Effect size: 'small' (0.20–0.49), 'moderate' (0.50–0.79), and 'large' (≥ 0.80).
ADL Activities of daily living, HADS Hospital Anxiety and Depression Scale, LEDD Levodopa equivalent daily dose, LEDD-DA LEDD of dopamine agonists, NMSS Non-Motor Symptom Scale, PDQ-8 SI Parkinson's Disease Questionnaire-8 Summary Index, SCOPA Scales for Outcome in Parkinson's Disease, UPDRS-III Unified Parkinson's Disease Rating Scale-motor examination.

Table 2 | Correlations between clinical characteristics at baseline and HADS-A change score anxiety cohort

	HADS-A change score		
	n	r	p-value
Age	50	−0.09	0.519
Disease duration	49	−0.19	0.198
HADS total	50	0.31	0.027
HADS-Anxiety	50	0.33	0.02
HADS-Depression	50	0.24	0.089
PDQ-8 Summary Index	50	0.12	0.413
NMSS total	50	0.14	0.344
UPDRS-III	49	0.24	0.105
SCOPA-M ADL	49	0.45	0.001
SCOPA-M motor complications	49	−0.05	0.742
LEDD total	50	−0.24	0.093
LEDD-DA	35	−0.16	0.355

Spearman correlations between HADS-A change score (baseline - 6-month follow-up) and clinical characteristics at baseline were calculated.
Bold font highlights significant results, *p* < 0.05; Positive correlations indicate that higher baseline values are associated with more postoperative improvement in anxiety.
ADL Activities of daily living, HADS Hospital Anxiety and Depression Scale, LEDD Levodopa equivalent daily dose, LEDD-DA LEDD of dopamine agonists, NMSS Non-Motor Symptom Scale, PDQ-8 SI Parkinson's Disease Questionnaire-8 Summary Index, SCOPA Scales for Outcome in Parkinson's Disease, UPDRS-III Unified Parkinson's Disease Rating Scale-motor examination.

up, total scores of outcome parameters improved similar to the anxiety cohort. In contrast to the anxiety cohort, the HADS-D subscale did not improve in the overall cohort.

Explorative correlation analyses between HADS-A change score and clinical characteristics at baseline for the overall cohort are shown in Supplementary Table 3. In the overall cohort, baseline HADS-A predicted HADS-A changes at 6-month follow-up ($\beta = 0.62$, $p < 0.001$). The multivariate multiple model accounted for 37.7% of the variance in HADS-A change.

The reduction of LEDD total was similar in the overall cohort and in the anxiety cohort (46.0%, respectively 45.1%), whereas the reduction of LEDD dopamine agonists was 47.3% in the overall cohort and only 28.4% in the anxiety cohort.

Discussion

In this prospective, open-label, multicentre study, we provide evidence that STN-DBS improves anxiety and that this improvement is associated with QoL improvement. We observed greater anxiety improvement in patients with worse baseline impairment of activities of daily living and urinary symptoms.

In line with the literature, we observed beneficial effects of STN-DBS on quality of life, motor and non-motor symptoms^{1,12}.

In the overall cohort, 33.1% of patients reported to have anxiety at baseline according to the established HADS-A cut-off. This is consistent with previous DBS studies (40%) and below the reported prevalence in the general PD population (55.8% in a large study including 1072 patients)^{4,13}. In line with a randomised, controlled study, we found a short-term improvement of anxiety measured with the HADS-A in our overall PD cohort⁸. Other studies have reported no change in anxiety using the State-Trait Anxiety Inventory (STAI) and the AMDP system (Association for Methodology and Documentation in Psychiatry) following bilateral STN-DBS, however both studies included small sample sizes of 27 and 15 patients respectively^{14,15}. In our cohort of patients undergoing STN-DBS, we found that the number needed to treat for a clinically relevant anxiety improvement was lower than for other treatments of PD¹⁶.

As regards clinical predictors of postoperative anxiety outcome, the present study provides a pioneer report that worse baseline impairment of ADL and urinary dysfunction are linked to greater improvement of anxiety at 6-month follow-up postoperatively. Partial correlations showed that depression was not a confounding factor in the predictor analyses of post-operative anxiety changes.

Anxiety and urinary symptoms have a shared pathophysiology through serotonergic pathways^{17,18} and impairments of sensory gating^{19,20}, which are improved by DBS^{20,21}. An argument in favour of the shared pathophysiology is that in the overall cohort including patients with less severe anxiety, we observed no significant relationship between these parameters.

Furthermore, worse urinary symptoms and other autonomic dysfunction result in an increase of ADL impairments, which in turn results in

worse anxiety²². In other words, ADL impairments mediate anxiety and urinary symptoms. In this context, in the general PD population, greater ADL impairments are related to worse anxiety²³ and our current study extends this finding to a DBS cohort.

Furthermore, in the overall cohort of our study, we confirm findings of a previous study, which reported that worse baseline HADS-A is a predictor of greater postoperative HADS-A improvement²⁴. This significant relationship was not reproduced in patients with baseline HADS-A ≥ 8 , possibly due to a statistical effect resulting from a homogenisation of independent variable data in the analysis. Closely connected to this point, as opposed to the multivariate multiple regression model in the anxiety cohort, baseline HADS-A was included as a predictor variable in the overall cohort and contributed to increase the explained variance of HADS-A outcome from 26.0% in the anxiety cohort to 37.7% in the overall cohort.

The relationship of anxiety and dopaminergic medication needs further discussion: Non-motor fluctuations and OFF periods are associated with anxiety and this results in an improvement of anxious symptoms when dopaminergic medication is optimised²⁵. In our cohort, we found that a reduction of LEDD total was not associated with the HADS-A change score. Therefore, the effect of STN-DBS goes beyond the amendment of total dopaminergic treatment. The reduction of LEDD of dopamine agonists was relatively small in the anxiety cohort. A possible explanation may be that dopamine agonists were tapered more cautiously in the anxiety cohort to prevent potential negative effects on mood symptoms, such as anxiety. Furthermore, our results show that LEDD total at baseline is not associated with change in anxiety.

Anxiety is related to sociodemographic parameters, motor symptoms, and quality of life. In line with the literature, we found a significant effect of STN-DBS on non-motor and motor symptoms, LEDD as well as QoL^{1,2}. In line with previous studies we found that anxiety improvement was directly proportionate to QoL improvement²⁶.

There are several limitations that need to be acknowledged. Firstly, our study included a relatively small sample size ($N = 151$ overall cohort and $N = 50$ anxious cohort). However, this is the only study investigating the effect of STN-DBS on anxiety in anxious patients at baseline. We addressed the effect of STN-DBS with a 6-month follow-up and, therefore, cannot conclude on the long-term effects of DBS on anxiety. Further longitudinal studies are required to explore this. Because clinically relevant neuropsychological and neuropsychiatric symptoms are considered contraindications for DBS treatment, baseline anxiety of patients in our study was mild to moderate and our observations need validation in a PD cohort with more severe anxiety. The HADS is useful for measuring the severity of anxiety²⁷. However, assessments of further anxiety scales may provide information on the severity of specific aspects of anxiety.

Urinary symptoms were only assessed using the validated NMSS and a clinical rating scale for urinary symptoms and/or an objective detailed urinary assessment including an urodynamic study might have increased the accuracy of our findings. Nevertheless, the NMSS has been listed as “suggested” severity scale to assess urinary symptoms in PD²⁸. Furthermore, we did not include a control group treated with best medical treatment and this should be considered in future studies. Closely connected to this point, a control group would help with the interpretation of the results of the number needed to treat analyses. Recently, we reported that more ventral locations of active DBS contacts are associated with greater improvement of anxiety²⁹. In our present study, we have not looked into stimulation parameters as we were interested in clinical baseline characteristics, which might predict the anxiety outcome. In this context, we have not assessed anxiety in MedOFF/StimON state, which would help to discriminate between pure neurostimulation effects on anxiety in specific STN subregions, such as its limbic part, from possible effects of dopaminergic medication on anxiety. Another limitation of our study is the lack of genetic characterization of the patients. A previous study found no differences in anxiety prevalence and severity between GBA-associated PD and compared to idiopathic PD. However other mutations may influence

anxiety prevalence and severity in patients and future studies should investigate the relationship of genetic mutations and non-motor and motor outcomes of DBS for PD.

In conclusion, we observed greater postoperative anxiety improvement in anxious patients with worse baseline impairment of ADL and urinary symptoms. Anxiety improvement was directly proportionate to QoL improvement.

This study emphasizes the importance of detailed preoperative motor and non-motor assessments and targeted measures to improve ADL and urinary symptoms in patients with anxiety undergoing STN-DBS for PD.

Methods

Study design and ethical approval

In this prospective, open-label, multicentre study we investigated patients undergoing STN-DBS with a 6-month follow-up^{30–32}. Consecutive patients were screened between August 2015 and March 2020. Written informed consent was given by all patients prior to study inclusion. The study was conducted under the Declaration of Helsinki and was approved by local ethics committees (German Clinical Trials Register: DRKS00006735, Cologne study no.: 12-145; Marburg study no.: 155/17, UK: National Research Ethics Service Southeast London REC3-10/H0808/141, 000010084).

Participants

PD diagnosis was established applying the UK Brain Bank criteria and patients were screened for DBS treatment according to the guidelines of the International PD and Movement Disorders Society^{30,33,34}. DBS indication evaluations were conducted in a case-based approach including a multi-disciplinary team of movement disorders neurologists, functional stereotactic neurosurgeons, psychiatrists experienced in DBS indication evaluations, speech and physiotherapists^{35,36}. Patients with clinically relevant neuropsychological impairments or psychiatric diseases including anxiety disorders according to the current edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) or International Statistical Classification of Diseases and Related Health Problems (ICD-10) were not eligible for DBS treatment^{37–40}. DBS surgical procedures are described elsewhere^{41,42}.

Clinical assessment

Clinical assessments were performed at preoperative baseline (MedON) and at 6-month follow-up after STN-DBS surgery (MedON/StimON)⁴³. MedON was achieved at least 30 min after the first morning dose of levodopa when patients as well as movement disorder specialists noted clinical improvements⁴⁴.

The main outcome was the anxiety subscale of the **Hospital Anxiety and Depression Scale (HADS)**:

The **HADS** is a 14-item self-report screening measure which is divided into a 7-item subscale for anxiety (HADS-A) and 7-item subscale for depression (HADS-D) and is commonly used in DBS studies^{45,46}. Both subscales range from 0 (no anxiety/depression) to 21 (maximum anxiety/depression). For both HADS-A and HADS-D, scale developers proposed a cut-off value of ≥ 8 for possible cases⁴⁷.

Furthermore, we assessed the following scales and parameters:

1. **NMS: The NMS Scale (NMSS)** is a clinician-rated tool containing 30 items divided into nine domains: 1) cardiovascular, 2) sleep/fatigue, 3) mood/apathy, 4) perceptual problems/hallucinations, 5) attention/memory, 6) gastrointestinal tract, 7) urinary, 8) sexual function, and 9) miscellaneous (including pain, inability to smell/taste, weight changes, and sweating) and records symptoms over the last four weeks. The NMSS is commonly used in DBS studies and its total score ranges from 0 (no NMS impairment) to 360 (maximum NMS impairment)^{30,48,49}.
2. **Motor disorder: Preoperative levodopa challenge tests** were assessed with the **UPDRS-III**, which ranges from 0 (no impairment) to 108 (maximum impairment)⁵⁰. Follow-up motor examination was assessed with the **UPDRS-III** (104 patients) or the **Scales for Outcomes in PD-motor scale (SCOPA-M; 47 patients)**. The SCOPA-M was derived

from the UPDRS, and the two scales highly correlate⁵¹. The SCOPA-M is commonly used for DBS studies and was chosen for time efficiency as its assessment time is approximately four times shorter than in the MDS-UPDRS^{52,53}. Based on previously published conversion methods⁵¹, we report motor examination as UPDRS-III to simplify the interpretation of data. Activities of daily living (ADL) and motor complications were assessed with dedicated parts of the SCOPA-M. The SCOPA-M parts for motor examination, ADL, and motor complications range from 0 (no impairment) to 42, 21, and 12 (maximum impairment), respectively⁵¹.

3. QoL: **PD Questionnaire-8 (PDQ-8)** is a well-established self-reported tool to measure QoL in PD patients and is commonly used in patients undergoing DBS^{11,54,55,56}. Furthermore, it is recommended by the International Parkinson and Movement Disorder Society⁵⁷. The data are expressed as **PDQ-Summary Index (SI)** ranging from 0 (no QoL impairment) to 100 (maximum QoL impairment).
4. Finally, the **levodopa equivalent daily dose (LEDD)** was calculated according to the method by Jost et al.⁵⁸.

Statistical analysis

Among the overall cohort undergoing STN-DBS we identified a subgroup of patients who experienced clinically relevant baseline anxious behaviour (cut-off value of HADS-A ≥ 8 ; hereinafter referred to as anxiety cohort).

Normality distribution of test scores was assessed using the Shapiro-Wilk method. Two-sided Wilcoxon signed-rank tests were employed to test for changes at 6-month follow-up. We corrected for multiple comparisons using the Bonferroni method and report adjusted *p*-values at the significance threshold of 0.05. We calculated relative change from baseline to follow-up [(mean Test_{baseline} – mean Test_{follow-up}) / mean Test_{baseline} x 100] and quantified effect size with Cohen's *d*⁵⁹. Effect size: 'small' (0.20–0.49), 'moderate' (0.50–0.79), and 'large' (≥ 0.80).

Following a method reported previously⁶⁰, we identified patients with a clinically relevant postoperative improvement of anxiety ('anxiety responders') based on a designated threshold of $\frac{1}{2}$ standard deviation (SD) of HADS-A_{baseline} in the overall cohort. Patients who did not improve beyond this threshold were categorised as 'anxiety non-responders'. In the anxiety cohort, we calculated the number needed to treat for a clinically relevant improvement of anxiety ($\text{NNT}_{\text{anxiety improvement}} = 1/\%$ of patients improving $>1/2$ SD of baseline HADS-A) and the number needed to treat for a remission of anxiety ($\text{NNT}_{\text{anxiety remission}} = 1/\text{absolute risk reduction of HADS-A} \geq 8$ from baseline to 6-month follow-up).

Subsequently, we explored the relationship between HADS-A change scores (Test_{baseline} – Test_{follow-up}) and preoperative demographic and clinical parameters using Spearman correlations. The correlations were categorised as following: 0.0–0.19 "very weak", 0.20–0.39 "weak", 0.40–0.59 "moderate", 0.60–0.79 "strong" and 0.80–1.0 "very strong".

To identify clinical predictors of anxious behaviour after 6 months of STN-DBS, simple univariate linear regressions with HADS-A change score as criterion variable were performed using candidate baseline predictor variables identified in correlation analyses (relaxed threshold $p < 0.20$)^{10,11}. Partial correlations were used to control for confounding effects of depression assessed with the baseline HADS-D.

In a second step, significant predictors identified in the simple univariate regression analyses were included as candidate predictors in a stepwise multiple univariate regression analysis with HADS-A change score as criterion variable. Multi-collinearity was checked using intercorrelations between significant predictor variables in the simple linear regression ($r < 0.6$).

All analyses were conducted using Statistical Package for Social Science (SPSS version 28.0). The code for running the regression analyses is published at <https://www.ibm.com/uk-en/analytics/spss-statistics-software>.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data used to support the findings of this study are available from the corresponding author upon reasonable request (specification of a clear research question and preparedness to enter legal data-sharing agreements).

Received: 21 September 2023; Accepted: 2 April 2024;

Published online: 08 June 2024

References

1. Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson's disease. *N. Engl. J. Med.* **355**, 896–908 (2006).
2. Dafsari, H. S. et al. Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease. *Eur. J. Neurol.* **26**, 222–e217 (2019).
3. Jost, S. T. et al. Neurostimulation for Advanced Parkinson Disease and Quality of Life at 5 Years: A Nonrandomized Controlled Trial. *JAMA Netw. Open* **7**, e2352177 (2024).
4. Barone, P. et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. *Mov. Disord.* **24**, <https://doi.org/10.1002/mds.22643> (2009).
5. Upneja, A., Paul, B. S., Jain, D., Choudhary, R. & Paul, G. Anxiety in Parkinson's Disease: Correlation with Depression and Quality of Life. *J. Neurosci. Rural Pract.* **12**, 323–328 (2021).
6. Chen, J. J. & Marsh, L. Anxiety in Parkinson's disease: identification and management. *Ther. Adv. Neurol. Disord.* **7**, 52–59 (2014).
7. Pontone, G. M. et al. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. *NPJ Parkinsons Dis.* **5**, 30 (2019).
8. Witt, K. et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. *Lancet Neurol.* **7**, 605–614 (2008).
9. Couto, M. I., Monteiro, A., Oliveira, A., Lunet, N. & Massano, J. Depression and anxiety following deep brain stimulation in Parkinson's disease: systematic review and meta-analysis. *Acta. Med. Port.* **27**, 372–382 (2014).
10. Gruber, D. et al. Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease. *J. Neural Trans. (Vienna, Austria)* **126**, 309–318 (2019).
11. Jost, S. T. et al. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. *NPJ Parkinsons Dis.* **7**, 48 (2021).
12. Jost, S. T. et al. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. *J. Neurol. Neurosurg. Psychiatry* **91**, 687–694 (2020).
13. Voon, V. et al. Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. *J. Neurosurg.* **103**, 246–251 (2005).
14. York, M. K. et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. *J. Neurol. Neurosurg. Psychiatry* **79**, 789–795 (2008).
15. Drapier, D. et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? *J. Neurol.* **253**, 1083–1091 (2006).
16. Ghielen, I. et al. The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: Two meta-analyses. *J. Psychosom. Res.* **122**, 43–51 (2019).
17. Zhang, F. et al. Subthalamic nucleus-deep brain stimulation improves autonomic dysfunctions in Parkinson's disease. *BMC Neurol.* **22**, 124 (2022).
18. Cao C.J., Y. S., Zuo L. J., et al. Study on the correlation of autonomic dysfunction with motor symptoms and non-motor symptoms in patients with Parkinson's disease. *Chin. J. Clin. (Electronic Edition)*, **7** (2013).
19. Storozeva, Z. I. et al. Sensorimotor and sensory gating in depression, anxiety, and their comorbidity. *World J. Biol. Psychiatry: Off. J. World Feder. Soc. Biol. Psychiatry* **22**, 183–193 (2021).

20. Herzog, J. et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. *Brain* **131**, 132–145 (2008).
21. Gulberti, A. et al. Subthalamic deep brain stimulation improves auditory sensory gating deficit in Parkinson's disease. *Clin. Neurophysiol. : Off. J. Int. Feder. Clin. Neurophysiol.* **126**, 565–574 (2015).
22. Cui, J. et al. Activities of daily living as a longitudinal moderator of the effect of autonomic dysfunction on anxiety and depression of Parkinson's patients. *Brain Behav.* **11**, e2297 (2021).
23. Dissanayaka, N. N. et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. *Movement Disord. : Off. J. Movement Disord. Soc.* **25**, 838–845 (2010).
24. Chang, B. et al. Development and Validation of a Prediction Model for Anxiety Improvement after Deep Brain Stimulation for Parkinson Disease. *Brain Sci.* **13**, 219 (2023).
25. Pontone, G. M. et al. 'Anxious fluctuators' a subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations. *Parkinsonism Relat. Disord.* **105**, 62–68 (2022).
26. Rodriguez-Blazquez, C. et al. Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease. *Mov. Disord.* **24**, 519–525 (2009).
27. Leentjens, A. F. et al. Anxiety rating scales in Parkinson's disease: a validation study of the Hamilton anxiety rating scale, the Beck anxiety inventory, and the hospital anxiety and depression scale. *Mov. Disord.* **26**, 407–415 (2011).
28. Pavy-Le Traon, A. et al. Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. *Mov. Disord. Clin. Pract.* **5**, 479–491 (2018).
29. Dafsari, H. S. et al. Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. *Brain Stimul.* **11**, 904–912 (2018).
30. Jost, S. T. et al. Gender gap in deep brain stimulation for Parkinson's disease. *NPJ Parkinsons Dis.* **8**, 47 (2022).
31. Dafsari, H. S. et al. Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinson's disease. *Brain Stimul.* **13**, 1697–1705 (2020).
32. Gronostay, A. et al. Stratifying quality of life outcome in subthalamic stimulation for Parkinson's disease. *J. Neurol. Neurosurg. Ps.* <https://doi.org/10.1136/jnnp-2023-332272> (2023).
33. Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* **55**, 181–184 (1992).
34. Lang, A. E. et al. Deep brain stimulation: preoperative issues. *Mov. Disord.* **21**, S171–S196 (2006).
35. Leta, V. et al. Personalised Advanced Therapies in Parkinson's Disease: The Role of Non-Motor Symptoms Profile. *J. Personal. Med.* **11**, 773 (2021).
36. Reker, P. et al. Gender differences in referrals for deep brain stimulation for essential tremor. *Parkinsonism Relat. Disord.* **112**, 105490 (2023).
37. Florin, E. et al. Modulation of local field potential power of the subthalamic nucleus during isometric force generation in patients with Parkinson's disease. *Neuroscience* **240**, 106–116 (2013).
38. Dafsari, H. S. et al. Subthalamic Stimulation Improves Quality of Life of Patients Aged 61 Years or Older With Short Duration of Parkinson's Disease. *Neuromodulation : J. Int. Neuromodulation Soc.* **21**, 532–540 (2018).
39. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders: DSM-5*. Vol. 5 (American psychiatric association Washington, DC, 2013).
40. World Health Organization. *The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines*. Vol. 1 (World Health Organization, 1992).
41. von Papen, M. et al. Phase-coherence classification: A new wavelet-based method to separate local field potentials into local (in)coherent and volume-conducted components. *J. Neurosci. Methods* **291**, 198–212 (2017).
42. Kocabicak, E. & Temel, Y. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: surgical technique, tips, tricks and complications. *Clin. Neurol. Neurosurg.* **115**, 2318–2323 (2013).
43. Schuepbach, W. M. M. et al. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. *Neurology* **92**, e1109–e1120 (2019).
44. Nettersheim, F. S. et al. Dopamine substitution alters effective connectivity of cortical prefrontal, premotor, and motor regions during complex bimanual finger movements in Parkinson's disease. *Neuroimage* **190**, 118–132 (2019).
45. Jost, S. T. et al. Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. *J. Parkinson's Dis.* **11**, 323–335 (2021).
46. Dafsari, H. S. et al. Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. *J. Neurol.* **267**, 1830–1841 (2020).
47. Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale. *Acta. Psychiatr. Scand.* **67**, 361–370 (1983).
48. Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. *Mov. Disord.* **22**, 1901–1911 (2007).
49. Sauerbier, A. et al. Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. *J. Parkinson's Dis.* **11**, 299–307 (2021).
50. Goetz, C. G. The Unified Parkinson's Disease Rating Scale (UPDRS): Status and Recommendations. *Mov. Disord.* **18**, 738–750 (2003).
51. Verbaan, D. et al. SPES/SCOPA and MDS-UPDRS: formulas for converting scores of two motor scales in Parkinson's disease. *Parkinsonism Relat. Disord.* **17**, 632–634 (2011).
52. Jost, S. T. et al. Non-motor effects of deep brain stimulation in Parkinson's disease motor subtypes. *Parkinsonism Relat. Disord.* 105318 (2023).
53. Lazcano-Ocampo, C. et al. Evaluation of the effect of bilateral subthalamic nucleus deep brain stimulation on fatigue in Parkinson's Disease as measured by the non-motor symptoms scale. *Br. J. Neurosurg.* 1–4 (2021).
54. Storch, A. et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. *Neurology* **80**, 800–809 (2013).
55. Sauerbier, A. et al. The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson's Disease. *J. Parkinson's Dis.* **12**, 453–464 (2022).
56. Alexander, P. et al. No evidence for an association of voxel-based morphometry with short-term non-motor outcomes in deep brain stimulation for Parkinson's disease. *Abstr npj Parkinson's Dis.* **10**, 91 (2024).
57. Martinez-Martin, P. et al. Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations. *Mov. Disord.* **26**, 2371–2380 (2011).
58. Jost, S. T. et al. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. *Mov. Disord.* <https://doi.org/10.1002/mds.29410> (2023).
59. Cohen, J. *Statistical power analysis for the behavioral sciences*. Vol. 8 (Academic Press 1977:8).
60. Sauerbier, A. et al. Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. *J. Neurol. Neurosurg. Psychiatry* **92**, 1313–1318 (2021).

Acknowledgements

The study center Marburg (PAL, CN, and LT) acknowledges Dr. D.J. Pedrosa for the allocation of patients to different research projects including the present study. This manuscript presents independent research funded by

the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London and Parkinson's UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, Parkinson's UK or the Department of Health. This manuscript presents independent research funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and King's College London and Parkinson's UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, Parkinson's UK or the Department of Health.

Author contributions

Anna Sauerbier – study concept and design, data acquisition, data analysis, drafting of the manuscript, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Johanna Herberg – data acquisition, data analysis, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Vasilija Stopic – data analysis, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Philipp A. Loehrer – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Keyoumars Ashkan – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Alexandra Rizos – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Stefanie T. Jost – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Jan Niklas Petry-Schmelzer – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Alexandra Gronostay – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Veerle Visser-Vandewalle – data acquisition, surgical intervention, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Julian Evans – data acquisition, surgical intervention, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Christopher Nimsky – data acquisition, surgical intervention, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Gereon R. Fink – interpretation of the data, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Angelo Antonini – interpretation of the data, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Pablo Martinez-Martin – interpretation of the data, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Monty Silverdale – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Daniel Weintraub – interpretation of the data, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Anette Schrag – interpretation of the data, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. K. Ray-Chaudhuri – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Lars Timmermann – data acquisition, critical revision of the manuscript for important intellectual content, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Haidar S. Dafsari – study concept and design, data acquisition, data analysis, drafting of the manuscript, final approval of the completed version, accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

Anna Sauerbier is funded by the Gussyk program and the Advanced Cologne Clinician Scientist program of the Medical Faculty of the University of Cologne and has received funding from the Prof. Klaus Thiemann Foundation. Johanna Herberg reports no financial disclosures. Vasilija Stopic is funded as part of the Advanced Cologne Clinician Scientist program. Philipp A. Loehrer was funded by the SUCCESS-Program of the University Hospital Marburg and the Parkinson's Foundation. He reports travel grants from AbbVie. Keyoumars Ashkan has received honoraria for educational meetings, travel and consultancy from Medtronic, St Jude Medical and Boston Scientific. Alexandra Rizos has received honorarium from UCB and was supported by a grant from Medtronic. Stefanie T. Jost has received funding from the Prof. Klaus Thiemann Foundation. Jan Niklas Petry-Schmelzer has been funded by the Cologne Clinician Scientist Program (CCSP)/ Faculty of Medicine/ University of Cologne. Funded by the German Research Foundation (DFG, FI 773/15-1) and received travel grants from Boston Scientific. Alexandra Gronostay reports no financial disclosures. Veerle Visser-Vandewalle is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID

431549029 – SFB 1451, is a member of the advisory boards and reports consultancies for Medtronic, Boston Scientific, Abbott, Insightec and Liva-Nova. Julian Evans reports no financial disclosures. Christopher Nimsky is consultant for Brainlab and received speaker's honoraria. Gereon R. Fink is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID 431549029 – SFB 1451. GRF serves as an editorial board member of *Cortex*, *Neurological Research and Practice*, *NeuroImage: Clinical*, *Zeitschrift für Neuropsychologie*, and *DGNeurologie*; receives royalties from the publication of the books *Funktionelle MRT in Psychiatrie und Neurologie*, *Neurologische Differentialdiagnose*, and *SOP Neurologie*; receives royalties from the publication of the neuropsychological tests *KAS* and *Köppts*; received honoraria for speaking engagements from Bayer, Desitin, DGN, Ergo DKV, Forum für medizinische Fortbildung FomF GmbH, GSK, Medica Academy Messe Düsseldorf, Medicbrain Healthcare, Novartis, Pfizer, and Sportärztebund NRW. Angelo Antonini reports personal consultancy fees from Zambon, AbbVie, Boehringer Ingelheim, GE, Neuroderm, Biogen, Bial, EVER Neuro Pharma, Therevance, Vectura grants from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 - PD_Pal Grant 825785, Ministry of Education University and Research (MIUR) Grant ARS01_01081, owns Patent WO2015110261-A1, owns shares from PD Neurotechnology Limited. Pablo Martinez-Martin has received honoraria from Editorial Viguera and Movement Disorder Society for lecturing in courses; from AbbVie for speaking in experts' meetings and from AbbVie and Zambon for participating in the Advisory Board of epidemiological studies. License fee payments for the King's Parkinson's Disease Pain Scale, and grants from the International Parkinson and Movement Disorder Society for development and validation of the MDS-Non-Motor Symptoms Scale. Monty Silverdale has received honoraria from Bial, Britannia and Medtronic. Daniel Weintraub reports no financial disclosures. Anette Schrag reports no financial disclosures. K. Ray Chaudhuri has received funding from Parkinson's UK, NIHR, UCB, and the European Union; he received honoraria from UCB, Abbott, Britannia, US Worldmeds, and Otsuka Pharmaceuticals; and acted as a consultant for AbbVie, UCB, and Britannia. Lars Timmermann reports grants, personal fees and non-financial support from SAPIENS Steering Brain Stimulation, Medtronic, Boston Scientific and St. Jude Medical. Haidar

S. Dafsari reports funding of his work by the EU Joint Programme—Neurodegenerative Disease Research (JPND), the Prof. Klaus Thiemann Foundation, the Felgenhauer Foundation, and the Koeln Fortune Program, and honoraria by Boston Scientific, Medtronic, Bial, and Stadapharm.

Additional information

Supplementary information The online version contains supplementary material available at

<https://doi.org/10.1038/s41531-024-00701-6>.

Correspondence and requests for materials should be addressed to Anna Sauerbier or Haidar S. Dafsari.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

¹University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany. ²Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. ³Department of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. ⁴Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK. ⁵University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, Cologne, Germany. ⁶Department of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK. ⁷Department of Neurosurgery, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. ⁸Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Jülich, Jülich, Germany. ⁹Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy. ¹⁰Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain. ¹¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-2676, USA. ¹²Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, UK.

✉ e-mail: anna.sauerbier@uk-koeln.de; haidar.dafsari@uk-koeln.de

EUROPAR, the German Parkinson Society Non-motor Symptoms Study Group, and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group

Charles Adler¹³, Roongroj Bhidayasiri¹⁴, Per Borghammer¹⁵, Paolo Barone¹⁶, David J. Brooks^{17,18}, Richard Brown¹⁹, Marc Cantillon²⁰, Camille Carroll²¹, Miguel Coelho²², Cristian Falup-Pecurariu²³, Tove Henriksen²⁴, Michele Hu^{25,26}, Peter Jenner²⁷, Beomseok Jeon²⁸, Milica Kramberger^{29,30}, Padma Kumar³¹, Mónica Kurtis³², Valentina Leta^{33,34}, Simon Lewis³⁵, Irene Litvan³⁶, Kelly Lyons³⁷, Davide Martino³⁸, Mario Masellis³⁹, Hideki Mochizuki⁴⁰, James F. Morley^{41,42}, Melissa Nirenberg⁴³, Per Odin⁴⁴, Javier Pagonabarraga⁴⁵, Jalesh Panicker⁴⁶, Nicola Pavese⁴⁷, Eero Pekkonen⁴⁸, Ron Postuma⁴⁹, Mayela Rodriguez Violante⁵⁰, Raymond Rosales^{51,52,53}, Anthony Schapira⁵⁴, Tanya Simuni⁵⁵, Fabrizio Stocchi⁵⁶, Alexander Storch^{57,58,59}, Indu Subramanian⁶⁰, Michele Tagliati⁶¹, Michele Tinazzi⁶², Jon Toledo^{63,64}, Yoshio Tsuboi⁶⁵ & Richard Walker⁶⁶

¹³The Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA. ¹⁴Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red

Cross Society, Bangkok, Thailand. ¹⁵Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark. ¹⁶Center for Neurodegenerative Diseases (CEMAND), Neuroscience Section, University of Salerno, Salerno, Italy. ¹⁷Institute of Neuroscience, Newcastle University, Newcastle, UK. ¹⁸Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark. ¹⁹King's College London, Department of Psychology, London, UK. ²⁰Reviva Pharmaceuticals, Inc., Santa Clara, CA, USA. ²¹Faculty of Medicine and Dentistry, University of Plymouth, Plymouth, UK. ²²FAS Center for Systems Biology, Harvard University, Cambridge, MA, USA. ²³Faculty of Medicine, Transilvania University of Braşov, Braşov, Romania. ²⁴Movement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, NV, Denmark. ²⁵Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK. ²⁶Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. ²⁷Neurodegenerative Diseases Research Group, Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, Newcomen Street, London, UK. ²⁸Department of Neurology, Seoul National University College of Medicine, Seoul, South Korea. ²⁹Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden. ³⁰Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia. ³¹Parkinson's Disease Service for the Older Person, Rankin Park Centre, John Hunter Hospital, HNELHD, Newcastle, NSW, Australia. ³²Functional Movement Disorders Unit, Movement Disorders Program, Neurology Department, Hospital Ruber Internacional, Madrid, Spain. ³³Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. ³⁴Parkinson's Centre of Excellence at King's College Hospital and King's College London, London, UK. ³⁵Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia. ³⁶Department of Neurosciences Movement Disorders Center, University of California, San Diego, USA. ³⁷University of Kansas Medical Center, Kansas City, KS, USA. ³⁸Department of Clinical Neurosciences, University of Calgary & Hotchkiss Brain Institute, Calgary, Canada. ³⁹Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada. ⁴⁰Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan. ⁴¹Parkinson Disease Research, Education, and Clinical Center, Philadelphia Veteran Affairs Medical Center, Philadelphia, PA, USA. ⁴²Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. ⁴³Department of Neurology, NYU School of Medicine, New York, NY, USA. ⁴⁴University of Lund, Faculty of Medicine, Lund, Sweden. ⁴⁵Movement Disorders Unit, Sant Pau Hospital and Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain. ⁴⁶Neurology, National Hospital for Neurology & Neurosurgery, London, UK. ⁴⁷Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Campus for Ageing & Vitality, Newcastle upon Tyne, UK. ⁴⁸Department of Neurology, Helsinki University Hospital, and Department of Neurological Sciences (Neurology), University of Helsinki, Helsinki, Finland. ⁴⁹Research Institute of McGill University Health Centre, Montréal, Canada. ⁵⁰Movement Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. ⁵¹Department of Neurology and Psychiatry, University of Santo Tomas Hospital, Manila 1008, Philippines. ⁵²International Institute of Neuroscience, Saint Luke's Medical Center, QUEZON, Philippines. ⁵³Center for Neurodiagnostic and Therapeutic Services, Metropolitan Medical Center, Manila 1000, Philippines. ⁵⁴Department of Clinical Neurosciences, University College London (UCL) Institute of Neurology, Royal Free Campus, Rowland Hill Street, London, UK. ⁵⁵Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. ⁵⁶University and Institute for Research and Medical Care, IRCCS San Raffaele, Rome, Italy. ⁵⁷Division of Neurodegenerative Diseases, Department of Neurology, Dresden University of Technology, Dresden, Germany. ⁵⁸Department of Neurology, Dresden University of Technology, Dresden, Germany. ⁵⁹German Center for Neurodegenerative Diseases (DZNE), Research Site Dresden, Dresden, Germany. ⁶⁰UCLA West LA VA, Los Angeles, CA, USA. ⁶¹Cedars-Sinai Medical Center, Los Angeles, CA, USA. ⁶²Department of Neuroscience, Biomedicine, and Movement, University of Verona, Verona, Italy. ⁶³Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁶⁴Department of Neurology, Houston Methodist Hospital, Houston, TX, USA. ⁶⁵Department of Neurology, Fukuoka University, Fukuoka, Japan. ⁶⁶Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear, UK. A full list of members and their affiliations appears in the Supplementary Information.